3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) - pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist

Details for Australian Patent Application No. 2007267197 (hide)

Owner High Point Pharmaceuticals, LLC

Inventors Hohlweg, Rolf

Agent Shelston IP

Pub. Number AU-B-2007267197

PCT Pub. Number WO2007/137968

Priority 06114615.5 29.05.06 EP; 06120117.4 05.09.06 EP

Filing date 22 May 2007

Wipo publication date 6 December 2007

Acceptance publication date 1 December 2011

International Classifications

C07D 405/04 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

A61K 31/501 (2006.01) - not condensed and containing further heterocyclic rings

Event Publications

6 November 2008 PCT application entered the National Phase

  PCT publication WO2007/137968 Priority application(s): WO2007/137968

13 October 2011 Amendment Made

  The nature of the amendment is: Amend the invention title to read 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist 2008

1 December 2011 Application Accepted

  Published as AU-B-2007267197

29 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007267203-Coffee capsule with a deformable sealing element

2007267191-Thiazole derivatives